More Imugene Ltd news
Imugene LtdASX: IMU

Clinical Trial Supply Agreement with Merck KGaA and Pfizer

Nov 15, 2021 at 9:35 PM EST · Issued by Imugene Ltd

Filed with ASX · Nov 15, 2021 at 9:35 PM EST

On 6ix: 6ix.com/news/clinical-trial-supply-agreement-with-merck-kgaa-and-pfizer

Imugene Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Imugene Ltd on 6ix

In the deck

  • Imugene — Shareholder Meeting (November 2021)11 slidesNov 19, 2021

Earlier from Imugene

  • Investor Presentation Imugene Eureka TherapeuticsOct 31, 2021
  • First patient dosed in Phase I clinical trial of CHECKvaccOct 20, 2021
  • Imugene HER-Vaxx Immunotherapy Patent Granted in JapanSep 21, 2021
  • S&P DJI Announces September 2021 Quarterly RebalanceSep 3, 2021
  • Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New TrialsAug 31, 2021

Later from Imugene

  • S&P DJI Announces December 2021 Quarterly RebalanceDec 3, 2021
  • Update on Clinical Trial of Oncolytic Virotherapy CHECKvaccDec 6, 2021
  • FDA IND approval for the phase 2 clinical trial of HER-VaxxDec 12, 2021
  • Imugene completes Phase 1a trial of immunotherapy PD1-VaxxJan 3, 2022
  • South Korea HERVaxx Patent GrantJan 5, 2022
All Imugene news releases↗

Follow Imugene into a list and get an email when it puts out news.

Follow Imugene
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer